**Etoricoxib: a French review of adverse effects**

- Peripheral oedema, and serious gastrointestinal, cardiovascular and cutaneous disorders.

Etoricoxib is a nonsteroidal anti-inflammatory drug (NSAID) said to selectively target cyclo-oxygenase-2. It has been marketed in France since 2010, for the treatment of osteoarthritis pain, despite having more adverse effects than other NSAIDs (1,2).

The Clermont-Ferrand Regional Pharmacovigilance Centre in France reviewed adverse effects attributed to etoricoxib between March 2010 and March 2012, based on data from the French pharmacovigilance system and the company that markets the drug (3).

The authors analysed 311 adverse effects that occurred in 207 patients with an average age of 63 years, 132 (64%) of whom were women. Half of the patients had taken etoricoxib for osteoarthritis, while the others were prescribed etoricoxib for off-label indications.

Adverse effects included renal disorders (5 cases of acute renal failure, 3 cases of nephrotic syndrome), cardiovascular events (35 cases of oedema, 22 cases of arterial hypertension, 7 cases of congestive heart failure, 14 arterial or venous thrombotic disorders), gastrointestinal disorders (including 3 gastrointestinal bleeds and 2 uncomplicated ulcers), 12 hypersensitivity reactions, and one case of toxic epidermal necrolysis (3). Two patients died.

In practice. When NSAID therapy is contemplated, it is best to use the well-documented drugs ibuprofen and naproxen, at the lowest effective dose. The marketing of etoricoxib exposes patients to more harms than benefits.

---

**Pregabalin: cardiac adverse effects**

- Rhythm and conduction disorders, heart failure, even at low doses.

Pregabalin is a gamma-aminobutyric acid (GABA) analogue closely related to gabapentin. It is used to treat neuropathic pain, generalised anxiety disorder, and partial seizures (1,2). Its adverse effect profile includes psychiatric disorders, abuse and addiction, gastrointestinal disorders, weight gain, skin rash, liver damage, visual field defects, and haematological disorders (1,3). Cases of heart failure have also been reported (1).

The Fernand-Widal Regional Pharmacovigilance Centre in Paris analysed 41 reports of cardiac adverse effects attributed to pregabalin in the French pharmacovigilance database (4).

Especially when used for neuropathic pain. The 26 women and 15 men concerned had a median age of 74 years and were mainly taking pregabalin for neuropathic pain. The cardiac adverse effects consisted of 25 cases of arrhythmia or conduction disorders (bradycardia, tachycardia, atrioventricular block, atrial fibrillation), 13 cases of heart failure, 5 cases of palpitations, and one myocardial infarction (he was also taking gemcitabine and cisplatin). Thirty-two of the 41 patients had a history of heart disorders (4).

In practice. When a patient taking pregabalin develops a cardiac disorder, the possible role of this drug should be considered, and pregabalin withdrawal may be warranted, especially in patients with a history of heart disease.